Mallinckrodt plc – OTC:MNKKQ

Mallinckrodt stock price today

$0.02
Financial Health
0
1
2
3
4
5
6
7
8
9

Mallinckrodt stock price monthly change

-74.52%
month

Mallinckrodt stock price quarterly change

-83.33%
quarter

Mallinckrodt key metrics

Market Cap
N/A
Enterprise value
2.71B
P/E
N/A
EV/Sales
2.93
EV/EBITDA
-2.52
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-21.61
Revenue
924.6M
EBITDA
-1.07B
Income
-780.6M
Revenue Q/Q
-29.77%
Revenue Y/Y
-62.80%
Profit margin
-84.4%
Oper. margin
-27.48%
Gross margin
-36.25%
EBIT margin
-27.48%
EBITDA margin
-116.26%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Mallinckrodt stock price history

Mallinckrodt stock forecast

Mallinckrodt financial statements

Mallinckrodt plc (OTC:MNKKQ): Profit margin
Sep 2021 507.2M -269M -53.04%
Dec 2021 -457.2M -197.6M 43.22%
Mar 2022 490.9M -120.2M -24.49%
Jul 2022 383.7M -193.8M -50.51%
Mallinckrodt plc (OTC:MNKKQ): Debt to assets
Sep 2021 9158000000 8.64B 94.39%
Dec 2021 329100000 491.3M 149.29%
Mar 2022 8704900000 8.50B 97.76%
Jul 2022 6485900000 4.34B 67.03%
Mallinckrodt plc (OTC:MNKKQ): Cash Flow
Sep 2021 82.4M -8.9M -4.7M
Dec 2021 0 0 0
Mar 2022 49.2M -23.4M -4.6M
Jul 2022 -691.5M -9.6M -274.1M

Mallinckrodt alternative data

Mallinckrodt plc (OTC:MNKKQ): Employee count
Aug 2023 2,778
Sep 2023 2,778
Oct 2023 2,778
Nov 2023 2,778
Dec 2023 2,778
Jan 2024 2,778
Feb 2024 2,778
Mar 2024 2,778
Apr 2024 2,778
May 2024 2,778
Jun 2024 2,778
Jul 2024 2,778

Mallinckrodt other data

Mallinckrodt plc (OTC:MNKKQ): Insider trades (number of shares)
Period Buy Sel
Aug 2021 0 7180
Mar 2022 0 34065
Transaction Date Insider Security Shares Price per share Total value Source
Sale
REED JOANN A director
Ordinary Shares 22,087 $0.12 $2,584
Sale
REED JOANN A director
Ordinary Shares 11,978 $0.12 $1,401
Sale
O'NEILL HUGH M. officer: EVP & Ch.. Ordinary Shares 2,100 $0.26 $538
Sale
NORTON DAVID Y director
Ordinary Shares 5,080 $0.26 $1,336
Sale
PAYA CARLOS V director
Ordinary Shares 16,614 $0.4 $6,712
Sale
CARROLL J MARTIN director
Ordinary Shares 31,398 $0.4 $12,591
Sale
CASEY MARK J officer: EVP and .. Ordinary Shares 15,291 $0.45 $6,881
Sale
NORTON DAVID Y director
Ordinary Shares 5,080 $0.4 $2,052
Sale
NORTON DAVID Y director
Ordinary Shares 21,807 $0.43 $9,464
Sale
CARLUCCI DAVID R director
Ordinary Shares 16,020 $0.14 $2,195
Monday, 2 December 2024
prnewswire.com
Monday, 18 November 2024
prnewswire.com
Thursday, 14 November 2024
prnewswire.com
Tuesday, 5 November 2024
prnewswire.com
Wednesday, 30 October 2024
prnewswire.com
Tuesday, 29 October 2024
prnewswire.com
Saturday, 26 October 2024
prnewswire.com
Thursday, 24 October 2024
prnewswire.com
Thursday, 10 October 2024
prnewswire.com
Wednesday, 3 August 2022
PRNewsWire
  • What's the price of Mallinckrodt stock today?

    One share of Mallinckrodt stock can currently be purchased for approximately $0.02.

  • When is Mallinckrodt's next earnings date?

    Unfortunately, Mallinckrodt's (MNKKQ) next earnings date is currently unknown.

  • Does Mallinckrodt pay dividends?

    No, Mallinckrodt does not pay dividends.

  • What is Mallinckrodt's stock symbol?

    Mallinckrodt plc is traded on the OTC under the ticker symbol "MNKKQ".

  • What is Mallinckrodt's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Mallinckrodt?

    Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Mallinckrodt's key executives?

    Mallinckrodt's management team includes the following people:

    • Mr. Mark Christopher Trudeau Pres, Chief Executive Officer & Director(age: 64, pay: $14,890,000)
    • Dr. Steven J. Romano M.D. Executive Vice President & Chief Scientific Officer(age: 66, pay: $4,780,000)
    • Mr. Hugh M. O'Neill Executive Vice President & Chief Commercial and Operations Officer(age: 62, pay: $4,730,000)
    • Mr. Mark J. Casey Executive Vice President & Chief Legal Officer(age: 62, pay: $4,380,000)
    • Mr. Bryan M. Reasons Executive Vice President & Chief Financial Officer(age: 58, pay: $4,100,000)
  • How many employees does Mallinckrodt have?

    As Jul 2024, Mallinckrodt employs 2,778 workers.

  • When Mallinckrodt went public?

    Mallinckrodt plc is publicly traded company for more then 12 years since IPO on 17 Jun 2013.

  • What is Mallinckrodt's official website?

    The official website for Mallinckrodt is mallinckrodt.com.

  • How can i contact Mallinckrodt?

    Mallinckrodt can be reached via phone at +353 1 696 0000.

Mallinckrodt company profile:

Mallinckrodt plc

mallinckrodt.com
Exchange:

OTC

Full time employees:

2,778

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

College Business & Technology Park
Dublin, 15

CIK: 0001567892
ISIN: IE00BBGT3753
: